Royal Bank Of Canada Solid Biosciences Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.51 - $7.56 $411 - $6,100	807 Added 29.12%	3,578 $1,000
Q2 2022 Aug 15, 2022	SELL	$0.43 - $1.24 $1,458 - $4,207	-3,393 Reduced 55.05%	2,771 $2,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.79 $5,285 - $12,784	-7,142 Reduced 53.68%	6,164 $7,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $7,408 - $10,784	4,384 Added 49.14%	13,306 $23,000
Q3 2021 Nov 15, 2021	SELL	$2.38 - $3.77 $6,330 - $10,028	-2,660 Reduced 22.97%	8,922 $21,000
Q2 2021 Aug 16, 2021	BUY	$3.49 - $5.51 $40,421 - $63,816	11,582 New	11,582 $42,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.